Press Releases Eli Lilly and Company

Equities

LLY

US5324571083

Pharmaceuticals

Market Closed - Nyse Other stock markets 04:00:02 2025-01-22 pm EST			After market 05:02:41 pm
753.98 ^USD	+1.57%		752.98	-0.13%

09:56am	Jefferies Adjusts Price Target on Eli Lilly to $1,020 From $996	MT
04:35am	Robeco Global Consumer Trends down 0.37% in December - up in Novo Nordisk and Eli Lilly	FW

Press Releases

Lilly IBD biologic receives expanded US approval	Jan. 16	AQ
FDA approves Lilly's Omvoh® (mirikizumab-mrkz) for Crohn's disease, expanding its use to the second major type of inflammatory bowel disease	Jan. 15	PR
Stock market today: Wall Street mostly rises after encouraging inflation data despite Lilly's drag	Jan. 14	AQ
Lilly provides update on 2024 revenue guidance, announces 2025 revenue guidance	Jan. 14	PR
Lilly to acquire Scorpion Therapeutics' mutant-selective PI3Kα inhibitor program	Jan. 13	PR
Lilly to participate in J.P. Morgan Healthcare Conference	Jan. 07	PR
Eli Lilly and Company - FDA approves Zepbound as the first and only prescription medicine for moderate-to-severe obstructive sleep apnea in adults with obesity	Dec. 23	AQ
FDA approves Zepbound® (tirzepatide) as the first and only prescription medicine for moderate-to-severe obstructive sleep apnea in adults with obesity	Dec. 20	PR
Stock market today: Wall Street leaps and halves its losses from what had been a dismal week	Dec. 20	AQ
Stock market today: Wall Street rallies to trim its losses from a rough week	Dec. 20	AQ
Lilly and EVA Pharma announce regulatory approval and release of locally manufactured insulin in Egypt	Dec. 17	PR
Lilly's Omvoh recommended by CHMP for approval in the European Union for adults with moderately to severely active Crohn's disease	Dec. 16	AQ
Lilly s Imlunestrant, an Oral SERD, Significantly Improved Progression-Free Survival as Monotherapy and in Combination with Verzenio in Patients with ER+, HER2- Advanced Breast Cancer	Dec. 12	AQ
Phase 3 results for Lilly's Jaypirca in covalent BTK inhibitor pre-treated chronic lymphocytic leukemia or small lymphocytic lymphoma to be presented at the 2024 ASH Annual Meeting	Dec. 10	AQ
Lilly announces new $15 billion share repurchase program and seventh consecutive 15% dividend increase	Dec. 09	PR
CORE Kidney, Boehringer Ingelheim and Lilly Are Turning Up the Volume on Kidney Health at the 2025 Tournament of Roses® Parade	Dec. 09	PR
Eli Lilly invests $3B to expand Wisconsin factory to help meet demand for Mounjaro, Zepbound	Dec. 05	AQ
Lilly announces $3 billion expansion of its recently acquired manufacturing facility in Wisconsin	Dec. 05	PR
Eli Lilly collaboration to accelerate biotech manufacturing	Dec. 05	AQ
Lilly's Zepbound superior to Wegovy in head-to-head trial showing an average weight loss of 20.2% vs. 13.7%	Dec. 05	AQ
Zepbound tops Wegovy for weight loss in Eli Lilly study	Dec. 04	AQ
Lilly's Zepbound® (tirzepatide) superior to Wegovy® (semaglutide) in head-to-head trial showing an average weight loss of 20.2% vs. 13.7%	Dec. 04	PR
GLP-1 Drugs: Brand Companies Push FDA To Limit Compounding	Dec. 03	AQ
Lilly announces changes on board of directors	Nov. 20	AQ
Eli Lilly and : Lilly announces changes on board of directors Form 8 K	Nov. 19	PU

Become a member to access more news.

100% Free Registration

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Eli Lilly CEO on Fighting Cancer and Obesity, Drug Pricing

January 13, 2025 at 11:30 am EST